Additionally, Kimball’s SUNSHINE and SUNRISE clinical trials demonstrated positive benefits of IL-17A inhibitor secukinumab in treating moderate to severe HS when administered every 2 weeks. Here, IL17A is linked to histiocytic sarcoma.